StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
20
This year
2
Publishing Date
2024 - 03 - 26
1
2024 - 03 - 19
1
2023 - 12 - 21
1
2023 - 09 - 25
1
2023 - 08 - 16
1
2023 - 04 - 11
1
2023 - 01 - 11
1
2022 - 10 - 14
1
2022 - 05 - 03
1
2022 - 04 - 19
1
2021 - 12 - 16
1
2021 - 10 - 12
1
2021 - 09 - 22
1
2021 - 09 - 17
1
2021 - 08 - 25
1
2021 - 08 - 03
1
2021 - 08 - 02
1
2021 - 07 - 28
1
2021 - 05 - 21
1
2021 - 04 - 14
1
Sector
Health technology
20
Tags
Alliances
16
Antibody
7
Application
11
Approval
20
Asia
15
Biotech
6
Biotech-bay
10
Biotech-beach
17
Cabometyx
7
Cancer
34
Cell carcinoma
7
Children
7
Clinical-trials-phase-ii
10
Clinical-trials-phase-iii
23
Collaboration
15
Covid
11
Covid-19
10
Disease
33
Drug
29
Earnings
23
Events
8
Expected
7
Fda
17
Financial
17
Financial results
13
Gene therapies
6
Gene therapy
6
Genetown
22
Global
51
Growth
29
Hereditary angioedema
8
Injection
6
Japan
7
License
13
Liver
16
Market
85
Money
11
N/a
185
Nivolumab
6
Partnership
6
People
7
Pharmaceutical
17
Phase 2
6
Phase 3
19
Positive
14
Product-news
10
Rare
11
Reach
12
Renal
7
Report
46
Research
41
Results
58
Sars-cov-2
6
Study
8
Takhzyro
7
Therapeutics
37
Therapy
43
Treatment
50
Trial
36
Vaccine
27
Entities
Arcturus therapeutics holdings inc.
5
Bristol-myers squibb company
3
Exelixis, inc.
4
Johnson & johnson
6
Novavax, inc.
1
Novo nordisk a/s
1
Pfizer, inc.
1
Sanofi
1
Takeda pharmaceutical company limited
20
Symbols
ABBV
37
ABT
24
ADCT
19
ADMA
17
AGIO
11
ALNY
13
AMGN
22
AMPH
9
AMRX
15
ANIP
17
ARGX
10
ARVL
14
ATLC
8
AVEO
20
BCRX
16
BGNE
24
BHC
8
BIIB
20
BMY
48
BPMC
23
BSX
8
CALT
8
CLVS
19
CNSP
11
EPZM
18
EXEL
14
FNCTF
21
FRG
15
GH
12
GILD
16
GSK
10
HALO
9
ILMN
12
IMAB
8
INCY
41
JAGX
8
JAZZ
8
JNJ
94
KMDA
11
KPTI
31
LLY
46
LTUM
11
MDT
28
MRK
8
NVAX
10
NVS
21
NVSEF
13
PFE
31
PRGO
21
REGN
32
RETA
9
RIGL
11
SNY
97
SNYNF
63
TAK
20
TEVJF
13
VRTX
8
VSTM
10
VTRS
8
YMAB
19
Exchanges
Nasdaq
11
Nyse
20
Crawled Date
2024 - 03 - 26
1
2024 - 03 - 19
1
2023 - 12 - 22
1
2023 - 09 - 25
1
2023 - 08 - 16
1
2023 - 04 - 11
1
2023 - 01 - 11
1
2022 - 10 - 14
1
2022 - 05 - 03
1
2022 - 04 - 19
1
2021 - 12 - 16
1
2021 - 10 - 12
1
2021 - 09 - 22
1
2021 - 09 - 17
1
2021 - 08 - 25
1
2021 - 08 - 03
1
2021 - 08 - 02
1
2021 - 07 - 28
1
2021 - 05 - 21
1
2021 - 04 - 15
1
Crawled Time
00:00
2
01:00
1
05:00
1
06:00
1
09:00
1
12:00
2
13:00
1
13:20
1
14:00
2
15:00
3
17:00
1
18:00
2
22:00
2
Source
www.biospace.com
18
www.prnewswire.com
2
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Approval
symbols :
TAK
save search
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Published:
2024-03-26
(Crawled : 18:00)
- biospace.com/
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
-7.07%
|
O:
1.84%
H:
0.24%
C:
-0.14%
adzynma
japan
takeda
approval
injection
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Published:
2024-03-19
(Crawled : 17:00)
- biospace.com/
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
-9.68%
|
O:
-0.07%
H:
0.0%
C:
-0.96%
iclusig
fda
drug
takeda
approval
application
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
Published:
2023-12-21
(Crawled : 00:00)
- biospace.com/
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
-3.94%
|
O:
2.05%
H:
0.29%
C:
0.0%
livtencity
approval
cytomegalovirus
treatment
china
Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
Published:
2023-09-25
(Crawled : 15:00)
- biospace.com/
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
-16.98%
|
O:
0.57%
H:
0.38%
C:
0.25%
japan
approval
Global Hemophilia Research Analysis Report 2023: A $21.07 Billion Market by 2030 - Approval of Gene Therapies and Monoclonal Antibodies Fueling Growth
Published:
2023-08-16
(Crawled : 01:00)
- prnewswire.com
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
-13.43%
|
O:
-0.26%
H:
0.26%
C:
-0.46%
PFE
A
|
$25.39
-0.12%
-0.12%
36M
|
Health Technology
|
-28.17%
|
O:
-0.71%
H:
1.45%
C:
0.97%
NVO
|
$122.75
-1.43%
0.0%
2.8M
|
Health Technology
|
34.55%
|
O:
-0.3%
H:
1.35%
C:
0.05%
SNY
|
News
|
$45.395
-1.55%
-1.58%
4.4M
|
Health Technology
|
-14.49%
|
O:
-1.33%
H:
0.0%
C:
0.0%
report
approval
research
global
growth
market
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children
Published:
2023-04-11
(Crawled : 13:20)
- biospace.com/
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
-20.88%
|
O:
-0.36%
H:
0.35%
C:
-0.12%
hyqvia
fda
children
approval
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC
Published:
2023-01-11
(Crawled : 14:00)
- biospace.com/
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
-14.61%
|
O:
1.04%
H:
0.32%
C:
0.19%
exkivity
approval
therapy
Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
Published:
2022-10-14
(Crawled : 15:00)
- biospace.com/
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
2.1%
|
O:
0.62%
H:
0.69%
C:
-0.69%
candidate
chmp
vaccine
dengue
approval
positive
tak-003
qdengue
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published:
2022-05-03
(Crawled : 18:00)
- biospace.com/
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
-9.25%
|
O:
0.41%
H:
0.0%
C:
0.0%
BMY
|
$48.3
0.96%
-0.1%
11M
|
Health Technology
|
-35.67%
|
O:
0.36%
H:
0.0%
C:
0.0%
EXEL
|
$22.47
-1.75%
-1.78%
2.6M
|
Health Technology
|
1.61%
|
O:
0.09%
H:
1.54%
C:
-0.44%
cabometyx
approval
cancer
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan
Published:
2022-04-19
(Crawled : 06:00)
- biospace.com/
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
-11.15%
|
O:
-2.23%
H:
0.0%
C:
0.0%
covid-19
nuvaxovid
vaccine
approval
Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine
Published:
2021-12-16
(Crawled : 05:00)
- prnewswire.com
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
-2.88%
|
O:
1.18%
H:
0.0%
C:
0.0%
NVAX
|
$3.9
0.26%
0.26%
2.8M
|
Health Technology
|
-97.71%
|
O:
5.55%
H:
0.0%
C:
0.0%
covid-19
new drug
application
drug
approval
covid
vaccine
submission
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published:
2021-10-12
(Crawled : 13:00)
- biospace.com/
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
-7.52%
|
O:
0.21%
H:
0.14%
C:
-1.05%
JNJ
|
News
|
$145.74
0.67%
0.0%
9.3M
|
Health Technology
|
-9.55%
|
O:
-0.16%
H:
0.11%
C:
-1.44%
ARCT
4
|
$26.31
-4.81%
-5.06%
610K
|
Health Technology
|
-38.76%
|
O:
4.89%
H:
1.6%
C:
-1.84%
vaccine
phase 3
approval
sars-cov-2
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published:
2021-09-22
(Crawled : 12:00)
- biospace.com/
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
-23.64%
|
O:
-0.17%
H:
0.0%
C:
-1.11%
JNJ
|
News
|
$145.74
0.67%
0.0%
9.3M
|
Health Technology
|
-11.9%
|
O:
0.5%
H:
0.36%
C:
-0.86%
ARCT
4
|
$26.31
-4.81%
-5.06%
610K
|
Health Technology
|
-49.2%
|
O:
1.81%
H:
2.1%
C:
-0.32%
phase 2
vaccine
phase 3
approval
sars-cov-2
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published:
2021-09-17
(Crawled : 22:00)
- biospace.com/
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
-23.55%
|
O:
-0.06%
H:
0.0%
C:
0.0%
EXEL
|
$22.47
-1.75%
-1.78%
2.6M
|
Health Technology
|
12.1%
|
O:
-0.61%
H:
0.0%
C:
0.0%
fda
fda approval
cancer
approval
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma
Published:
2021-08-25
(Crawled : 22:00)
- biospace.com/
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
-22.0%
|
O:
-0.24%
H:
0.27%
C:
0.0%
BMY
|
$48.3
0.96%
-0.1%
11M
|
Health Technology
|
-29.51%
|
O:
-0.38%
H:
0.07%
C:
-0.97%
EXEL
|
$22.47
-1.75%
-1.78%
2.6M
|
Health Technology
|
21.63%
|
O:
-0.37%
H:
2.23%
C:
0.27%
treatment
renal
approval
cell carcinoma
nivolumab
Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study
Published:
2021-08-03
(Crawled : 12:00)
- biospace.com/
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
-21.45%
|
O:
-0.06%
H:
0.0%
C:
-0.6%
JNJ
|
News
|
$145.74
0.67%
0.0%
9.3M
|
Health Technology
|
-15.86%
|
O:
0.27%
H:
1.02%
C:
0.96%
ARCT
4
|
$26.31
-4.81%
-5.06%
610K
|
Health Technology
|
-24.06%
|
O:
13.79%
H:
51.6%
C:
47.69%
phase 1
vaccine
trial
approval
sars-cov-2
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
Published:
2021-08-02
(Crawled : 14:00)
- biospace.com/
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
-21.87%
|
O:
-0.36%
H:
0.75%
C:
-0.18%
JNJ
|
News
|
$145.74
0.67%
0.0%
9.3M
|
Health Technology
|
-15.94%
|
O:
0.02%
H:
0.21%
C:
-0.12%
ARCT
4
|
$26.31
-4.81%
-5.06%
610K
|
Health Technology
|
-15.07%
|
O:
6.36%
H:
9.92%
C:
5.16%
vaccine
trial
approval
sars-cov-2
Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
Published:
2021-07-28
(Crawled : 15:00)
- biospace.com/
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
-21.59%
|
O:
0.42%
H:
2.14%
C:
1.72%
JNJ
|
News
|
$145.74
0.67%
0.0%
9.3M
|
Health Technology
|
-16.05%
|
O:
0.04%
H:
0.38%
C:
-0.32%
ARCT
4
|
$26.31
-4.81%
-5.06%
610K
|
Health Technology
|
-15.34%
|
O:
-0.19%
H:
6.93%
C:
6.54%
phase 2
approval
Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan
Published:
2021-05-21
(Crawled : 09:00)
- biospace.com/
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
-24.08%
|
O:
0.75%
H:
0.63%
C:
-0.17%
JNJ
|
News
|
$145.74
0.67%
0.0%
9.3M
|
Health Technology
|
-15.27%
|
O:
0.15%
H:
0.82%
C:
-0.22%
covid
vaccine
approval
covid-19
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Published:
2021-04-14
(Crawled : 00:00)
- biospace.com/
TAK
|
News
|
$13.16
0.08%
0.0%
1.3M
|
Health Technology
|
-22.65%
|
O:
0.0%
H:
1.09%
C:
0.35%
BMY
|
$48.3
0.96%
-0.1%
11M
|
Health Technology
|
-24.03%
|
O:
0.27%
H:
0.33%
C:
0.09%
EXEL
|
$22.47
-1.75%
-1.78%
2.6M
|
Health Technology
|
-1.69%
|
O:
-0.38%
H:
4.2%
C:
3.09%
treatment
europe
renal
approval
cell carcinoma
nivolumab
Gainers vs Losers
64%
36%
Top 10 Gainers
AGBA
|
News
|
$1.02
155.0%
57.94%
120M
|
Finance
ZCMD
|
$2.86
108.76%
52.1%
2.3M
|
Commercial Services
INVO
|
$1.555
104.6%
51.13%
5M
|
Health Technology
ISPC
|
$0.437
105.16%
49.53%
37M
|
Professional, Scientific, and T...
WLGS
|
News
|
$0.92
84.0%
45.65%
1.6M
|
OST
|
$0.499
21.38%
45.26%
1.9M
|
XPON
|
News
|
$3.1
60.62%
37.74%
17M
|
TIRX
|
$0.7
44.39%
30.74%
58M
|
BNTC
|
News
|
$6.92
44.17%
30.64%
3.5M
|
Health Technology
GGE
|
$0.035
19.86%
29.3%
64M
|
Your saved searches
Save your searches and get alerts when important news are released.